Figure 7

Phase 2: Serum (A) anti-insulin IgG, (B) anti-CTB IgG, (C,D) anti-insulin IgA, and (E,F) anti-CTB IgA were measured at 4, 8, and 12 weeks of age via ELISA. (A) Anti-insulin IgG was elevated in untreated and WT tobacco treated animals at 12 weeks of age relative to 4 weeks of age, P < 0.0001. (B) Anti-CTB IgG did not differ significantly across treatment groups over time, P = 0.37. (C) Serum anti-insulin IgA levels (as measured by absolute OD) were significantly higher in phase 1 CTB-hpINS treated mice (positive control) compared to all time points and treatment groups except for 12 week-old GAD tobacco treated animals, P < 0.0001, but (D) at 12 weeks of age, there was no difference between treatment groups as measured by OD fold change, P = 0.43. (E) At 12 weeks of age, anti-CTB IgA was elevated in mice that received combination therapy as measured by absolute OD, P < 0.01, but (F) the difference was not significant when measured by OD fold change at 12 weeks of age, P = 0.07 (ANOVA).